Amgen Inc. (AMGN)

業務介紹

Amgen Inc.（安进公司）在全球范围内发现、开发、制造和提供人类治疗药物。它专注于炎症、肿瘤/血液学、骨健康、心血管疾病、肾病学和神经科学领域。该公司的产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病性关节炎的恩布瑞（Enbrel）；用于减少癌症患者低白细胞计数引起的感染风险的新乐斯达（Neulasta）；用于治疗绝经后骨质疏松症的普罗利亚（Prolia）；用于预防与骨骼相关事件的克吉瓦（Xgeva）；用于治疗成年患者斑块型银屑病、银屑病性关节炎和与贝赫切特病相关的口腔溃疡的奥特兹拉（Otezla）；用于治疗红细胞数量低于正常水平和贫血的阿拉尼斯（Aranesp）；用于治疗复发或难治性多发性骨髓瘤的凯普罗利斯（KYPROLIS）；以及用于降低心肌梗死、中风和冠状动脉重建风险的瑞帕塔（Repatha）。它还销售Nplate、Vectibix、MVASI、Parsabiv、EPOGEN、KANJINTI、BLINCYTO、Aimovig、EVENITY、AMGEVITATM、Sensipar/Mimpara、NEUPOGEN、IMLYGIC、Corlanor和AVSOLA等产品。Amgen Inc.为医疗保健提供者提供服务，包括医生或他们的诊所、透析中心、医院和药店。它通过制药批发经销商以及直销渠道分销其产品。该公司与诺华制药股份有限公司、UCB、拜耳医疗保健有限责任公司、BeiGene有限公司、礼来公司、Datos Health和Verastem公司达成合作协议，评估VS-6766与lumakrastm（Sotorasib）联合应用于KRAS G12C突变非小细胞肺癌患者。它与协和制药株式会社达成协议，共同开发和商业化KHK4083，这是一种用于治疗特应性皮炎和其他自身免疫性疾病的第三阶段准备就绪的OX40全人源单克隆抗体；并与Neumora Therapeutics公司和Plexium公司进行研发合作。Amgen Inc.成立于1980年，总部位于加利福尼亚州千橡市。

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

公司網址

https://www.amgen.com